Global Oncology Cytotoxic Drug
Global Oncology Cytotoxic Drug

Oncology Cytotoxic Drug Comprehensive Study by Application (Breast Cancer, Blood Cancer, Prostate Cancer, Respiratory, Lung Cancer), (), Dosage (Injection, Solid Oral Dose Forms, Others) Players and Region - Global Market Outlook to 2025

Oncology Cytotoxic Drug Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Dec 2020 Edition 200 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Oncology Cytotoxic Drug Market Scope
The global oncology cytotoxic drugs market is expected to grow in the forecast period due to the availability of novel drugs, the presence of a strong pipeline, and supportive government legislation for disease awareness. Besides this, the growing incidence of cancer, coupled with the increasing geriatric population and unorganized lifestyle, is driving the market. However, adverse effects associated with the use of drugs and high costs related to drug development are the major factors that impede the growth of the market.

The Oncology Cytotoxic Drug market study is segmented, by Application (Breast Cancer, Blood Cancer, Prostate Cancer, Respiratory and Lung Cancer) and major geographies with country level break-up.

The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Oncology Cytotoxic Drug market throughout the predicted period.

Roche Holding AG (Switzerland), Eli Lilly (United States), Celgene (United States), Sanofi (France), Eisai (Japan), Sumitomo Dainippon Pharma (Japan), Seattle Genetics (United States), Takeda Pharmaceutical Company (Japan), Hansoh Pharma (China) and Novartis (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are AstraZeneca (United Kingdom), Jazz Pharmaceuticals (Ireland) and Spectrum Pharmaceuticals (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Oncology Cytotoxic Drug market by Type, Application and Region.

On the basis of geography, the market of Oncology Cytotoxic Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
In Dec 2018, AstraZeneca announced a new collaboration with Cancer Research UK to launch a centre of excellence in genetic screening, cancer modelling and big data processing aimed at accelerating the discovery of new cancer medicines.
In Dec 2019, Johnson & Johnson runs the financial assistance programs available for DOXIL used in the treatment of cancer that provide free or low-cost health coverage to patients. This was carried out to expand the treatment options and gain a competitive advantage.


Market Drivers
  • Increase in Incidence of Cancer Across the Globe
  • Growth in Global Geriatric Population
  • Rise in Government Expenditures on Healthcare

Opportunities
  • Untapped Market of Emerging Economies
  • Strong R&D Initiatives from Key Players

Restraints
  • Adverse effects associated with the use of cancer drugs

Challenges
  • The Role of Cytotoxic Drugs in Cancer Therapy Has Decreased Slightly With the Development of Drug Therapy


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Oncology Cytotoxic Drug Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Application
  • Breast Cancer
  • Blood Cancer
  • Prostate Cancer
  • Respiratory
  • Lung Cancer
By Dosage
  • Injection
  • Solid Oral Dose Forms
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Incidence of Cancer Across the Globe
      • 3.2.2. Growth in Global Geriatric Population
      • 3.2.3. Rise in Government Expenditures on Healthcare
    • 3.3. Market Challenges
      • 3.3.1. The Role of Cytotoxic Drugs in Cancer Therapy Has Decreased Slightly With the Development of Drug Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Oncology Cytotoxic Drug, by Application, , Dosage and Region (value and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Oncology Cytotoxic Drug (Value)
      • 5.2.1. Global Oncology Cytotoxic Drug by: Application (Value)
        • 5.2.1.1. Breast Cancer
        • 5.2.1.2. Blood Cancer
        • 5.2.1.3. Prostate Cancer
        • 5.2.1.4. Respiratory
        • 5.2.1.5. Lung Cancer
      • 5.2.2. Global Oncology Cytotoxic Drug by: Dosage (Value)
        • 5.2.2.1. Injection
        • 5.2.2.2. Solid Oral Dose Forms
        • 5.2.2.3. Others
      • 5.2.3. Global Oncology Cytotoxic Drug Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Oncology Cytotoxic Drug (Price)
  • 6. Oncology Cytotoxic Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche Holding AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eli Lilly (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Celgene (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eisai (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sumitomo Dainippon Pharma (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Seattle Genetics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Takeda Pharmaceutical Company (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Hansoh Pharma (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Oncology Cytotoxic Drug Sale, by Application, , Dosage and Region (value and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Oncology Cytotoxic Drug (Value)
      • 7.2.1. Global Oncology Cytotoxic Drug by: Application (Value)
        • 7.2.1.1. Breast Cancer
        • 7.2.1.2. Blood Cancer
        • 7.2.1.3. Prostate Cancer
        • 7.2.1.4. Respiratory
        • 7.2.1.5. Lung Cancer
      • 7.2.2. Global Oncology Cytotoxic Drug by: Dosage (Value)
        • 7.2.2.1. Injection
        • 7.2.2.2. Solid Oral Dose Forms
        • 7.2.2.3. Others
      • 7.2.3. Global Oncology Cytotoxic Drug Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Oncology Cytotoxic Drug (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Oncology Cytotoxic Drug: by Application(USD Million)
  • Table 2. Oncology Cytotoxic Drug Breast Cancer , by Region USD Million (2014-2019)
  • Table 3. Oncology Cytotoxic Drug Blood Cancer , by Region USD Million (2014-2019)
  • Table 4. Oncology Cytotoxic Drug Prostate Cancer , by Region USD Million (2014-2019)
  • Table 5. Oncology Cytotoxic Drug Respiratory , by Region USD Million (2014-2019)
  • Table 6. Oncology Cytotoxic Drug Lung Cancer , by Region USD Million (2014-2019)
  • Table 7. Oncology Cytotoxic Drug: by Dosage(USD Million)
  • Table 8. Oncology Cytotoxic Drug Injection , by Region USD Million (2014-2019)
  • Table 9. Oncology Cytotoxic Drug Solid Oral Dose Forms , by Region USD Million (2014-2019)
  • Table 10. Oncology Cytotoxic Drug Others , by Region USD Million (2014-2019)
  • Table 11. South America Oncology Cytotoxic Drug, by Country USD Million (2014-2019)
  • Table 12. South America Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 13. South America Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 14. Brazil Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 15. Brazil Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 16. Argentina Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 17. Argentina Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 18. Rest of South America Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 19. Rest of South America Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 20. Asia Pacific Oncology Cytotoxic Drug, by Country USD Million (2014-2019)
  • Table 21. Asia Pacific Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 22. Asia Pacific Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 23. China Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 24. China Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 25. Japan Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 26. Japan Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 27. India Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 28. India Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 29. South Korea Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 30. South Korea Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 31. Taiwan Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 32. Taiwan Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 33. Australia Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 34. Australia Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 35. Rest of Asia-Pacific Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 36. Rest of Asia-Pacific Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 37. Europe Oncology Cytotoxic Drug, by Country USD Million (2014-2019)
  • Table 38. Europe Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 39. Europe Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 40. Germany Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 41. Germany Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 42. France Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 43. France Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 44. Italy Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 45. Italy Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 46. United Kingdom Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 47. United Kingdom Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 48. Netherlands Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 49. Netherlands Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 50. Rest of Europe Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 51. Rest of Europe Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 52. MEA Oncology Cytotoxic Drug, by Country USD Million (2014-2019)
  • Table 53. MEA Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 54. MEA Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 55. Middle East Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 56. Middle East Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 57. Africa Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 58. Africa Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 59. North America Oncology Cytotoxic Drug, by Country USD Million (2014-2019)
  • Table 60. North America Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 61. North America Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 62. United States Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 63. United States Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 64. Canada Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 65. Canada Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 66. Mexico Oncology Cytotoxic Drug, by Application USD Million (2014-2019)
  • Table 67. Mexico Oncology Cytotoxic Drug, by Dosage USD Million (2014-2019)
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Oncology Cytotoxic Drug: by Application(USD Million)
  • Table 79. Oncology Cytotoxic Drug Breast Cancer , by Region USD Million (2020-2025)
  • Table 80. Oncology Cytotoxic Drug Blood Cancer , by Region USD Million (2020-2025)
  • Table 81. Oncology Cytotoxic Drug Prostate Cancer , by Region USD Million (2020-2025)
  • Table 82. Oncology Cytotoxic Drug Respiratory , by Region USD Million (2020-2025)
  • Table 83. Oncology Cytotoxic Drug Lung Cancer , by Region USD Million (2020-2025)
  • Table 84. Oncology Cytotoxic Drug: by Dosage(USD Million)
  • Table 85. Oncology Cytotoxic Drug Injection , by Region USD Million (2020-2025)
  • Table 86. Oncology Cytotoxic Drug Solid Oral Dose Forms , by Region USD Million (2020-2025)
  • Table 87. Oncology Cytotoxic Drug Others , by Region USD Million (2020-2025)
  • Table 88. South America Oncology Cytotoxic Drug, by Country USD Million (2020-2025)
  • Table 89. South America Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 90. South America Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 91. Brazil Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 92. Brazil Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 93. Argentina Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 94. Argentina Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 95. Rest of South America Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 96. Rest of South America Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 97. Asia Pacific Oncology Cytotoxic Drug, by Country USD Million (2020-2025)
  • Table 98. Asia Pacific Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 99. Asia Pacific Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 100. China Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 101. China Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 102. Japan Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 103. Japan Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 104. India Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 105. India Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 106. South Korea Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 107. South Korea Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 108. Taiwan Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 109. Taiwan Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 110. Australia Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 111. Australia Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 112. Rest of Asia-Pacific Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 113. Rest of Asia-Pacific Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 114. Europe Oncology Cytotoxic Drug, by Country USD Million (2020-2025)
  • Table 115. Europe Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 116. Europe Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 117. Germany Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 118. Germany Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 119. France Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 120. France Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 121. Italy Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 122. Italy Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 123. United Kingdom Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 124. United Kingdom Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 125. Netherlands Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 126. Netherlands Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 127. Rest of Europe Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 128. Rest of Europe Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 129. MEA Oncology Cytotoxic Drug, by Country USD Million (2020-2025)
  • Table 130. MEA Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 131. MEA Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 132. Middle East Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 133. Middle East Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 134. Africa Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 135. Africa Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 136. North America Oncology Cytotoxic Drug, by Country USD Million (2020-2025)
  • Table 137. North America Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 138. North America Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 139. United States Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 140. United States Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 141. Canada Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 142. Canada Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 143. Mexico Oncology Cytotoxic Drug, by Application USD Million (2020-2025)
  • Table 144. Mexico Oncology Cytotoxic Drug, by Dosage USD Million (2020-2025)
  • Table 145. Research Programs/Design for This Report
  • Table 146. Key Data Information from Secondary Sources
  • Table 147. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Oncology Cytotoxic Drug: by Application USD Million (2014-2019)
  • Figure 5. Global Oncology Cytotoxic Drug: by Dosage USD Million (2014-2019)
  • Figure 6. South America Oncology Cytotoxic Drug Share (%), by Country
  • Figure 7. Asia Pacific Oncology Cytotoxic Drug Share (%), by Country
  • Figure 8. Europe Oncology Cytotoxic Drug Share (%), by Country
  • Figure 9. MEA Oncology Cytotoxic Drug Share (%), by Country
  • Figure 10. North America Oncology Cytotoxic Drug Share (%), by Country
  • Figure 11. Global Oncology Cytotoxic Drug share by Players 2019 (%)
  • Figure 12. Global Oncology Cytotoxic Drug share by Players (Top 3) 2019(%)
  • Figure 13. Global Oncology Cytotoxic Drug share by Players (Top 5) 2019(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 16. Roche Holding AG (Switzerland) Revenue: by Geography 2019
  • Figure 17. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 18. Eli Lilly (United States) Revenue: by Geography 2019
  • Figure 19. Celgene (United States) Revenue, Net Income and Gross profit
  • Figure 20. Celgene (United States) Revenue: by Geography 2019
  • Figure 21. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 22. Sanofi (France) Revenue: by Geography 2019
  • Figure 23. Eisai (Japan) Revenue, Net Income and Gross profit
  • Figure 24. Eisai (Japan) Revenue: by Geography 2019
  • Figure 25. Sumitomo Dainippon Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 26. Sumitomo Dainippon Pharma (Japan) Revenue: by Geography 2019
  • Figure 27. Seattle Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 28. Seattle Genetics (United States) Revenue: by Geography 2019
  • Figure 29. Takeda Pharmaceutical Company (Japan) Revenue, Net Income and Gross profit
  • Figure 30. Takeda Pharmaceutical Company (Japan) Revenue: by Geography 2019
  • Figure 31. Hansoh Pharma (China) Revenue, Net Income and Gross profit
  • Figure 32. Hansoh Pharma (China) Revenue: by Geography 2019
  • Figure 33. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Novartis (Switzerland) Revenue: by Geography 2019
  • Figure 35. Global Oncology Cytotoxic Drug: by Application USD Million (2020-2025)
  • Figure 36. Global Oncology Cytotoxic Drug: by Dosage USD Million (2020-2025)
  • Figure 37. South America Oncology Cytotoxic Drug Share (%), by Country
  • Figure 38. Asia Pacific Oncology Cytotoxic Drug Share (%), by Country
  • Figure 39. Europe Oncology Cytotoxic Drug Share (%), by Country
  • Figure 40. MEA Oncology Cytotoxic Drug Share (%), by Country
  • Figure 41. North America Oncology Cytotoxic Drug Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Roche Holding AG (Switzerland)
  • Eli Lilly (United States)
  • Celgene (United States)
  • Sanofi (France)
  • Eisai (Japan)
  • Sumitomo Dainippon Pharma (Japan)
  • Seattle Genetics (United States)
  • Takeda Pharmaceutical Company (Japan)
  • Hansoh Pharma (China)
  • Novartis (Switzerland)
Additional players considered in the study are as follows:
AstraZeneca (United Kingdom) , Jazz Pharmaceuticals (Ireland) , Spectrum Pharmaceuticals (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation